Saicun Biotechnology
Cryopreservation solutions for biological samples.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY20.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Saicun Biotechnology, also known as CellStore Bio, is a life sciences company founded in 2022 and headquartered in Beijing, China. The company develops and produces advanced cryopreservation technology for biological samples, targeting biomedical enterprises and research institutions.
The core of its business is providing customized biological sample cryopreservation solutions through contract research organization (CRO) services. This involves the research, development, and production of new-generation technologies designed to ensure the safe and effective long-term storage of biological materials. The company's business model appears to be a combination of technology licensing and fee-for-service revenue, a common approach for platform-technology biotechs.
Saicun Biotechnology has successfully attracted venture capital, indicating investor confidence in its potential. The company completed a Seed Round in January 2023, followed by an Early Stage VC round in February 2024. Key investors include MiraclePlus, Thunderstorm VC, Y&R Capital, and Ruisheng Equity, among others. This funding supports the company's research and development efforts to advance its cryopreservation solutions.
Keywords: cryopreservation, biological samples, cell storage, biotechnology, life sciences, CRO services, biomedical research, sample preservation, cryopreservation technology, biomedical enterprises, R&D, venture capital, asset creation, biopharma